Dr. Hobbs on the Role of Molecular Testing to Determine Resistance in CML
Gabriela Hobbs, MD, discusses the role of molecular testing to determine resistance in chronic myeloid leukemia.
Dr. Hobbs on Choosing Optimal Second-Line Treatment Option for TKI-Resistant CLL
Gabriela Hobbs, MD, shares advice on how to choose the appropriate second-line treatment option for patients with chronic lymphocytic leukemia who are resistant to TKIs.
Dr. Hobbs on Managing Ponatinib-Associated Toxicities in CML
Gaby Hobbs, MD, discusses managing ponatinib-associated toxicities in chronic myeloid leukemia.
Dr. Hobbs Discusses the Treatment Landscape of CML
Gabriela S. Hobbs, MD, clinical director, Leukemia Service, assistant in medicine, Massachusetts General Hospital, discusses the treatment landscape of chronic myeloid leukemia.
Dr. Hobbs on the Updated NCCN Guidelines in CML
Gabriela S. Hobbs, MD, clinical director, Leukemia Service, assistant in medicine, Massachusetts General Hospital, discusses the updated NCCN guidelines in chronic myeloid leukemia (CML).
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
2 Clarke Drive Cranbury, NJ 08512